Items
Linked e-resources
Details
Table of Contents
Monograph overview / Jeffrey S. Abrams, Patricia Eifel
National Institutes of Health Consensus Development Conference statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 / National Institutes of Health Consensus Development Panel
Adjuvant therapy for breast cancer: current controversies and future prospects / William C. Wood
Interpreting and integrating risk factors for patients with primary breast cancer / Gary M. Clark
Traditional and newer pathologic factors / Stuart J. Schnitt
Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer / Maria Grazia Daidone, Rosella Silvestrini
Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women / James J. Dignam
Adjuvant therapy for very young women with breast cancer: need for tailored treatments / Aron Goldhirsch ... [et al.]
Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status / Hyman B. Muss
Duration of adjuvant tamoxifen therapy / John Bryant, Bernard Fisher, James Dignam
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in Stage 1 breast cancer / Bernard Fisher ... [et al.]
Ovarian ablation as adjuvant therapy for breast cancer / Nancy E. Davidson
Progress in systemic chemotherapy of primary breast cancer: an overview / Gabriel N. Hortobagyi
Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes / Peter Marcus Ravdin
Is Her-2/neu a predictor of anthracycline utility? No / George W. Sledge, Jr.
Texanes in the adjuvant treatment of breast cancer: why not yet? / Martine J. Piccart ... [et al.]
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 / Norman Wolmark ... [et al.]
Who should not receive adjuvant chemotherapy?: international databases / Jonas Bergh, Marit Holmquist
Who should not receive chemotherapy?: data from American databases and trials / Monica Morrow, Helen Krontiras
Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer / Karen H. Antman
Treatment guidelines and techniques in delivery of postmastectomy radiotherapy in management of operable breast cancer / Lori J. Pierce
Side effects, quality-of-life issues, and trade-offs: the patient perspective / Amy S. Langer
Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life / Patricia A. Ganz
Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer / Ann H. Partridge, Harold J. Burstein, Eric P. Winer
Decision-making process, communicating risk/benefits: is there an ideal technique? / Mark Levine, Tim Whelan
Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? / R. John Simes, Alan S. Coates.
National Institutes of Health Consensus Development Conference statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000 / National Institutes of Health Consensus Development Panel
Adjuvant therapy for breast cancer: current controversies and future prospects / William C. Wood
Interpreting and integrating risk factors for patients with primary breast cancer / Gary M. Clark
Traditional and newer pathologic factors / Stuart J. Schnitt
Prognostic and predictive role of proliferation indices in adjuvant therapy of breast cancer / Maria Grazia Daidone, Rosella Silvestrini
Efficacy of systemic adjuvant therapy for breast cancer in African-American and Caucasian women / James J. Dignam
Adjuvant therapy for very young women with breast cancer: need for tailored treatments / Aron Goldhirsch ... [et al.]
Factors used to select adjuvant therapy of breast cancer in the United States: an overview of age, race, and socioeconomic status / Hyman B. Muss
Duration of adjuvant tamoxifen therapy / John Bryant, Bernard Fisher, James Dignam
Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in Stage 1 breast cancer / Bernard Fisher ... [et al.]
Ovarian ablation as adjuvant therapy for breast cancer / Nancy E. Davidson
Progress in systemic chemotherapy of primary breast cancer: an overview / Gabriel N. Hortobagyi
Is Her2 of value in identifying patients who particularly benefit from anthracyclines during adjuvant therapy? A qualified yes / Peter Marcus Ravdin
Is Her-2/neu a predictor of anthracycline utility? No / George W. Sledge, Jr.
Texanes in the adjuvant treatment of breast cancer: why not yet? / Martine J. Piccart ... [et al.]
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 / Norman Wolmark ... [et al.]
Who should not receive adjuvant chemotherapy?: international databases / Jonas Bergh, Marit Holmquist
Who should not receive chemotherapy?: data from American databases and trials / Monica Morrow, Helen Krontiras
Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer / Karen H. Antman
Treatment guidelines and techniques in delivery of postmastectomy radiotherapy in management of operable breast cancer / Lori J. Pierce
Side effects, quality-of-life issues, and trade-offs: the patient perspective / Amy S. Langer
Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life / Patricia A. Ganz
Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer / Ann H. Partridge, Harold J. Burstein, Eric P. Winer
Decision-making process, communicating risk/benefits: is there an ideal technique? / Mark Levine, Tim Whelan
Patient preferences for adjuvant chemotherapy of early breast cancer: how much benefit is needed? / R. John Simes, Alan S. Coates.